(Bloomberg) — Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound.
Most Read from Bloomberg
The company also raised its quarterly dividend 15%, according to a statement Monday. The shares rose as much as 1.3% in late trading after the US markets closed.
The share repurchases may be made from time to time at management’s discretion, Lilly said.
Most Read from Bloomberg Businessweek
©2024 Bloomberg L.P.
Source: finance.yahoo.com
Related posts:
3 High-Yield Dividend Stocks to Buy and Hold Forever
Fearing a hawkish Fed? Here’s what’s likely limiting more downside in the stock market, according to...
Oppenheimer Bullish on These 2 Stocks for 70% Upside (Or More)
Thousands of student loans to be canceled in Navient settlement: How to find out if you're eligible
Warren Buffett’s Berkshire Hathaway Bought These Stocks Last Quarter